CytomX Therapeutics, Inc. (NASDAQ:CTMX) Shares Sold by Virtu Financial LLC

Virtu Financial LLC lessened its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX) by 35.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 57,012 shares of the biotechnology company’s stock after selling 31,506 shares during the quarter. Virtu Financial LLC owned 0.07% of CytomX Therapeutics worth $59,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. FMR LLC lifted its position in shares of CytomX Therapeutics by 17.3% during the 3rd quarter. FMR LLC now owns 284,307 shares of the biotechnology company’s stock valued at $335,000 after acquiring an additional 41,949 shares during the period. Geode Capital Management LLC raised its holdings in CytomX Therapeutics by 4.4% during the third quarter. Geode Capital Management LLC now owns 803,531 shares of the biotechnology company’s stock worth $948,000 after purchasing an additional 34,032 shares during the last quarter. Miller Financial Services LLC acquired a new position in CytomX Therapeutics during the fourth quarter worth $26,000. Traphagen Investment Advisors LLC purchased a new stake in CytomX Therapeutics during the fourth quarter worth $31,000. Finally, Monimus Capital Management LP acquired a new stake in CytomX Therapeutics in the fourth quarter valued at $375,000. Institutional investors and hedge funds own 67.77% of the company’s stock.

CytomX Therapeutics Price Performance

NASDAQ:CTMX opened at $0.64 on Tuesday. The firm has a market cap of $50.93 million, a PE ratio of 3.74 and a beta of 1.05. The firm has a 50 day simple moving average of $0.74 and a 200-day simple moving average of $0.95. CytomX Therapeutics, Inc. has a 1-year low of $0.56 and a 1-year high of $5.85.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, March 6th. The biotechnology company reported $0.22 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.45. The company had revenue of $38.09 million during the quarter, compared to the consensus estimate of $13.53 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. As a group, sell-side analysts expect that CytomX Therapeutics, Inc. will post -0.05 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on CTMX shares. HC Wainwright reaffirmed a “neutral” rating on shares of CytomX Therapeutics in a research note on Friday, March 7th. StockNews.com downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Monday. Finally, Wedbush reissued an “outperform” rating and set a $5.00 price objective on shares of CytomX Therapeutics in a research note on Friday, March 7th. Four investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $5.02.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.